HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 23, No 11, November 2019 – Evaluating cost effectiveness of genomic profiling       » Ion treatment offers new hope for cancer patients       » Empowering sustainability through innovation       » Meeting clinical needs in Asia with HealthTech       » The key in diagnosis and treatment       » Singapore's first private co-working laboratory and office space       » Singapore-based MedTech company announced as winner of 2019 Asia Pacific Showcase Competition at The MedTech Forum      
EDITOR'S LETTER
Regeneration: from fighting to building

Regenerative medicine is an area of medicine with the potential to fully heal damaged tissues and organs, offering solutions and hope for people who have conditions today that are beyond repair. It is a branch of biomedical translational research that “replaces or regenerates human cells, tissues or organs, to restore or establish normal function”.

It involves the use of stem cells (cell therapies) and transplantation of in vitro grown organs and tissues (tissue engineering). Blood transfusions and bone marrow transplants are the most common forms.

What distinguishes regenerative medicine apart from traditional drugs is that the latter mostly treat symptoms, whereas the former aims to treat the root cause of a patient's condition by replacing lost cells or organs, or by fixing a faulty gene.

In a report published in 2017 in The Lancet, scientists observed that the number of regenerative medicine treatments in medical use today is very low. Only a handful of breakthroughs made it to patients, and private clinics are cashing in on patients' desperate search for treatments by offering unproven therapies. This combination of poor quality science, unclear funding models, unrealistic hopes and unscrupulous private clinics threatens regenerative medicine's social license to operate.

Experimental regenerative medicine treatments are being carried out in animals. At the Veterinary Health Center at Kansas State University, it is offering platelet-rich plasma and animal stem cell therapies for horses suffering from osteoarthritis, tendon injuries and ligament tears. The initial studies are promising, however the professors warned that there needs to be validated scientific protocols and sound clinical decision-making to minimise the variables associated with the actual stem cells used in each horse.

In another report published in 2018 by Stem Cells Translational Medicine, researchers have developed a simple, minimally invasive, effective way to treat osteoarthritis in dogs, using adipose (fat) tissues.

These studies in animals underscores the need to transition this technology to human clinical trials.

Despite the successes in these new therapies studies, regenerative medicine treatments have not entered mainstream medical practice. The Lancet report suggests that "the potential exists to substantially reduce the burden of disease for some common conditions (e.g. stroke, heart disease, progressive neurological conditions, autoimmune diseases, and trauma)".

Let’s cell-ebrate this advancement of science and technology, enhancing the lives of people and animals around the world.


Lim Guan Yu
APBN Editor
You can reach me at gylim@wspc.com

 

You can always access all APBN's issues on our website: www.asiabiotech.com.
Check us out at Facebook @Asia Pacific Biotech News, Instagram @asiabiotech, or follow us on Twitter @asia_biotech.

 
Click here for the complete issue.

NEWS CRUNCH  
news ECV2019 China Healthcare and Pharma Digital Innovation Summit Held Successfully in Shanghai — The "Highway" Era of Healthcare Digital Transformation
news Natural Extracts Innovated, Transformed and Diversely Laid Out to Embrace the Blue Ocean Market of Big Health
news The Proteona Oncology Challenge using ESCAPETM Single Cell Proteogenomic Analysis
news New computational fluid dynamics solution for modeling aerosol mixtures in biomedical and environmental research
PR NEWSWIRE  
Asia Pacific Biotech News
SPOTLIGHT  
LIFE OF A SCIENTIST  

APBN Editorial Calendar 2019
January:
Taiwan Medical tourism
February:
Marijuana as medicine — Legal marijuana will open up scientific research
March:
Driven by curiosity
April:
Career developments for researchers
May:
What's cracking — Antibodies in ostrich eggs
June:
Clinical trials — What's in a name?
July:
Traditional Chinese medicine in modern healthcare — Integrating both worlds
August:
Digitalization vs Digitization — Exploring Emerging Trends in Healthcare
September:
Healthy Ageing — How Science is chipping in
October:
Disruptive Urban Farming — Microbes, Plasmids, and Recycling
November:
Evaluating cost effectiveness of genomic profiling
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2019 World Scientific Publishing Co Pte Ltd  •  Privacy Policy